How to solve the price dispute?

Drugs are perhaps the most controversial of all goods and services traded in a market economy, according to China report hall Although drugs are produced by private enterprises, they are part of the public interest, not only because they can prevent epidemic diseases, but also because healthy people can better maintain social operation than patients Drugs have the moral weight that most privately traded goods do not, because it is generally believed that everyone should have the right to health care, but not everyone should have a smartphone or running shoes Innovation constitutes the vast majority of the cost of drugs, so the price of drugs is much higher than the cost of their production and processing, which makes many poor people unable to bear the cost of drugs Companies protect the intellectual property rights that drugs represent and Sue individuals and companies that try to make and sell patented drugs at low prices For all these reasons, pharmaceutical companies are generally regarded as vampires who exploit patients and ignore the suffering of the poor Refer to the 2012-2016 China traditional Chinese medicine industry status observation and investment prospect analysis report released by China report hall More than a decade ago, when the spread of AIDS was at its worst, there was growing criticism of pharmaceutical companies At that time, the South African government tried to legalize the cheap generic imitation of imported patented anti AIDS drugs, but the pharmaceutical companies sued the South African government The case is known as "big pharma V Nelson Mandela" This is the bottom of the pharmaceutical industry, but pharmaceutical companies have wisely chosen to back down Now, the issue of drug pricing has been raised again Activists are suing the court to prevent a new hepatitis C drug from being patented in India The drug has just been approved by US regulators There are also small conflicts unfolding, involving countries from Brazil to the UK But the main battleground is the trans Pacific Partnership, a trade agreement between several countries in Asia and several countries in the Americas The agreement has yet to be agreed, in part because of pricing problems Relevant drug price Research Report 2013-2018 China taxi operation status analysis report 2013-2018 e-commerce industry development special research report 2013-2017 financial leasing special research report 2013-2017 Bank of China financial products market depth evaluation and investment prospect forecast report 2013-2017 China logistics industry investment prospect forecast report more pharmaceutical industry analysis According to the trade related aspects of intellectual property rights signed in 1994, governments can allow non patent drug manufacturers to produce patent drugs The U.S has most of the world's largest pharmaceutical companies, and its consumers buy the most expensive drugs in the world, thus keeping the price of drugs at a low level for people in other countries The United States wants to use TPP to restrict the compulsory licensing of patents for infectious diseases, while emerging market countries want to make it more difficult for pharmaceutical companies to obtain patents The reason why the drug price dispute will break out again is not because of an emergency, but because of a wide range of long-term changes Rich countries want to cut medical costs In emerging markets, people are living longer, and many are suffering from diseases that are more prevalent in rich countries This increases the demand for drugs to treat cancer, diabetes and other chronic diseases In emerging markets, governments want to expand coverage, but drugs already account for a large part of health care spending - 44% in India and 43% in China, but only 12% in the UK and the US In 2012, US regulators approved 39 drugs, the most since 1996 In particular, cancer treatment is entering a new era In the period of the most serious AIDS, there are many reasons to support patent compulsory licensing The reason is that during the epidemic period, the coverage of anti epidemic drugs should be as wide as possible, so as to prevent the further spread of the epidemic But compulsory licensing can also hinder innovation; and it will get worse as emerging markets contribute more and more to the revenue of pharmaceutical companies More importantly, as emerging countries become more prosperous, so do their elites; moreover, it is unreasonable for poor Americans to provide medical subsidies to rich Indians The problem is different now - most diseases come steadily with age, and rarely break out of control This requires the formulation of specific medical policies By diversifying drug prices - Americans and Britons, for example, pay more than Africans - pharmaceutical companies can increase their profits while expanding their markets, benefiting both shareholders and patients Some companies are trying this Roche, a Swiss company, has created new brands and packaging for low-cost drugs sold in India and Egypt However, the so-called "tiered pricing" also has risks Some people may buy drugs from countries with low drug prices, and then sell them in countries with high drug prices, so as to make intermediate profits Therefore, more sophisticated pricing needs to be supported by more stringent systems, which should ensure that intellectual property rights will not be removed by law or damaged by illegal trade In view of this, although the United States is heavily biased towards pharmaceutical companies, it is pushing TPP in the right direction More compulsory licensing is not in the interests of patients around the world; it is in their interests to protect pharmaceutical patents.